Malaria Vaccination Turns Mosquito Bites Into Immune Boosters

Key takeaways:

• WEHI researchers developed a malaria vaccination strategy that uses mosquito-delivered parasites to stimulate durable immunity.
• Experimental drugs WM382 and MK-7602 stopped malaria parasites during the late liver stage, before they entered the bloodstream.
• The approach generated both antibody and CD8+ T-cell responses, including liver-resident memory T cells.
• In mice, protection lasted for up to two years, supporting further research into long-lasting malaria prevention.
• Researchers envision a future “vaccinate and boost naturally” strategy for malaria-endemic regions.

How can malaria vaccination use mosquito bites to build immunity?

Malaria vaccination could take an unconventional direction by using controlled mosquito bites as repeated immune-boosting events. Researchers at WEHI in Melbourne, Australia, demonstrated a preclinical approach that combines small doses of mosquito-transmitted malaria parasites with investigational antimalarial compounds.

Published in Science, the study targeted the parasite during the late liver stage of malaria infection. At this point, the parasites had multiplied but had not yet entered the bloodstream to cause disease.

The researchers used WM382 and MK-7602, dual inhibitors of plasmepsin IX and X, enzymes that regulate parasite survival. These compounds arrested parasite development at this critical stage, allowing the immune system to encounter a broader range of malaria antigens without progressing to symptomatic disease.

What immune response did the experimental malaria vaccination strategy generate?

The approach produced a multi-layered immune response despite using a relatively small parasite dose. Researchers observed antibody production alongside CD8+ T-cell responses, including liver-resident memory T cells that can rapidly respond to future infections.

This distinction could matter for malaria prevention because these immune cells remain positioned at the site where parasites initially develop after mosquito transmission. By stopping the parasite immediately before it causes bloodstream infection, the strategy may give the immune system a broader preview of potential threats.

In mice, the experimental vaccination strategy protected against malaria for up to two years during the study period. Researchers noted that this duration could correspond to two malaria seasons in real-world endemic settings.

Could mosquito bites become natural malaria boosters?

The findings raise the possibility of a “vaccinate and boost naturally” model, in which repeated mosquito exposures could reinforce immunity in malaria-endemic communities.

The researchers stressed that the findings remain preclinical, and further studies must establish whether the strategy is safe, effective, and practical for humans. A long-acting injectable formulation based on the compounds is also in preclinical development.

With more than 600,000 malaria-related deaths reported annually and drug resistance complicating disease control, new prevention strategies remain a major priority. The conserved targets of WM382 and MK-7602 could protect multiple malaria species, although this requires clinical validation.

For more updates, register for Infectious Diseases CME Conferences & Online Courses

For infectious disease specialists, tropical medicine clinicians, vaccinologists, and researchers, the study highlights how chemovaccination could complement existing malaria prevention approaches by combining controlled parasite exposure with targeted drug-mediated protection.

Source:

Walter and Eliza Hall Institute